A reference set of clinically relevant adverse drug-drug interactions
Open Access
- 4 March 2022
- journal article
- research article
- Published by Springer Nature in Scientific Data
- Vol. 9 (1) , 1-9
Abstract
The accurate and timely detection of adverse drug-drug interactions (DDIs) during the postmarketing phase is an important yet complex task with potentially major clinical implications. The development of data mining methodologies that scan healthcare databases for drug safety signals requires appropriate reference sets for performance evaluation. Methodologies for establishing DDI reference sets are limited in the literature, while there is no publicly available resource simultaneously focusing on clinical relevance of DDIs and individual behaviour of interacting drugs. By automatically extracting and aggregating information from multiple clinical resources, we provide a scalable approach for generating a reference set for DDIs that could support research in postmarketing safety surveillance. CRESCENDDI contains 10,286 positive and 4,544 negative controls, covering 454 drugs and 179 adverse events mapped to RxNorm and MedDRA concepts, respectively. It also includes single drug information for the included drugs (i.e., adverse drug reactions, indications, and negative drug-event associations). We demonstrate usability of the resource by scanning a spontaneous reporting system database for signals of DDIs using traditional signal detection algorithms.Keywords
Funding Information
- RCUK | Engineering and Physical Sciences Research Council (EP/R51231X/1)
- AstraZeneca
This publication has 29 references indexed in Scilit:
- Understanding and preventing drug–drug and drug–gene interactionsExpert Review of Clinical Pharmacology, 2014
- Epidemiology and characteristics of adverse drug reactions caused by drug–drug interactionsExpert Opinion on Drug Safety, 2011
- Black Box Warning Contraindicated Comedications: Concordance Among Three Major Drug Interaction Screening ProgramsAnnals of Pharmacotherapy, 2010
- Evaluation of frequently used drug interaction screening programsPharmacy World & Science, 2008
- A statistical methodology for drug–drug interaction surveillanceStatistics in Medicine, 2008
- Detecting signals of drug–drug interactions in a spontaneous reports databaseBritish Journal of Clinical Pharmacology, 2007
- Comparative assessment of four drug interaction compendiaBritish Journal of Clinical Pharmacology, 2006
- Disproportionality analysis using empirical Bayes data mining: a tool for the evaluation of drug interactions in the post‐marketing settingPharmacoepidemiology and Drug Safety, 2003
- Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reportsPharmacoepidemiology and Drug Safety, 2001
- Disagreement among drug compendia on inclusion and ratings of drug-drug interactionsCurrent Therapeutic Research, 2000